Design and Evaluation of a Carrier-Free Prodrug-Based Palmitic–DEVD–Doxorubicin Conjugate for Targeted Cancer Therapy
Bioconjugate Chemistry · 2023
DOI: 10.1021/acs.bioconjchem.2c00490 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2023. Verfasst von Seong-Bin Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Life Science, Graduate School, BK21 Program, Konkuk University, Chungju 27478, Republic of Korea. Hauptthemen laut MEDLINE: Prodrugs, Antineoplastic Agents, Nanoparticles, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Research Council of Science and Technology, National Research Foundation of Korea, Korea Basic Science Institute.
Abstract (Originalsprache)
In the development of new drugs, typical polymer- or macromolecule-based nanocarriers suffer from manufacturing process complexity, unwanted systematic toxicity, and low loading capacity. However, carrier-free nanomedicines have made outstanding progress in drug delivery and pharmacokinetics, demonstrating most of the advantages associated with nanoparticles when applied in targeted anticancer therapy. Here, to overcome the problems of nanocarriers and conventional cytotoxic drugs, we developed a novel, carrier-free, self-assembled prodrug consisting of a hydrophobic palmitic (16-carbon chain n-hexadecane chain) moiety and hydrophilic group (or moiety) which is included in a caspase-3-specific cleavable peptide (Asp-Glu-Val-Asp, DEVD) and a cytotoxic drug (doxorubicin, DOX). The amphiphilic conjugate, the palmitic-DEVD-DOX, has the ability to self-assemble into nanoparticles in saline without the need for any carriers or nanoformulations. Additionally, the inclusion of doxorubicin is in its prodrug form and the apoptosis-specific DEVD peptide lead to the reduced side effects of doxorubicin in normal tissue. Furthermore, the carrier-free palmitic-DEVD-DOX nanoparticles could passively accumulate in the tumor tissues of tumor-bearing mice due to an enhanced permeation and retention (EPR) effect. As a result, the palmitic-DEVD-DOX conjugate showed an enhanced therapeutic effect compared with the unmodified DEVD-DOX conjugate. Therefore, this carrier-free palmitic-DEVD-DOX prodrug has great therapeutic potential to treat solid tumors, overcoming the problems of conventional chemotherapy and nanoparticles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Applied Life Science, Graduate School, BK21 Program, Konkuk University, Chungju 27478, Republic of Korea.
- Department of Biomedical Chemistry, College of Biomedical and Health Science, Konkuk University, Chungju 27478, Republic of Korea.
- College of Biomedical and Health Science, Konkuk University, Chungju 27478, Republic of Korea.
- College of Pharmacy, Chungnam National University, Daejeon 34134, Republic of Korea.
- Research Center for Bioconvergence Analysis, Korea Basic Science Institute (KBSI), Ochang, Chungbuk 28119, Republic of Korea.
- Bio-Analytical Science, University of Science and Technology, Daejeon 34113, Republic of Korea.
ORCID-Profile: Young-Ho Lee, Jooho Park
Förderung
- National Research Council of Science and Technology
- National Research Foundation of Korea
- Korea Basic Science Institute
Zitieren
APA
Yang, S. B., Lee, D. N., Lee, J. H., Seo, M., Shin, D. W., Lee, S., Lee, Y. H., & Park, J. (2023). Design and Evaluation of a Carrier-Free Prodrug-Based Palmitic–DEVD–Doxorubicin Conjugate for Targeted Cancer Therapy. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.2c00490
Vancouver
Yang SB, Lee DN, Lee JH, Seo M, Shin DW, Lee S, et al. Design and Evaluation of a Carrier-Free Prodrug-Based Palmitic–DEVD–Doxorubicin Conjugate for Targeted Cancer Therapy. Bioconjugate Chemistry. 2023. doi:10.1021/acs.bioconjchem.2c00490
BibTeX
@article{Yang2023,
author = {Yang, Seong-Bin and Lee, Dong-Nyeong and Lee, Jun-Hyuck and Seo, Minho and Shin, Dong Wook and Lee, Seokwoo and Lee, Young-Ho and Park, Jooho},
title = {Design and Evaluation of a Carrier-Free Prodrug-Based Palmitic–DEVD–Doxorubicin Conjugate for Targeted Cancer Therapy},
journal = {Bioconjugate Chemistry},
year = {2023},
doi = {10.1021/acs.bioconjchem.2c00490}
}
EUVIMED